Dupilumab
Mechanism :
Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signalling by binding to the IL-4Ra subunit.
Indication :
- Off-Label: Asthma, moderate to severe (uncontrolled)
- Atopic dermatitis: Treatment of moderate to severe atopic dermatitis in adults
Contraindications :
Known hypersensitivity to dupilumab or any component of the formulation.
Dosing :
In patients aged ≥12 years with eosinophilic phenotype or PO corticosteroid dependent asthma.
400 mg SC once, then 200 mg once in 2 weeks.
Atopic dermatitis:
Adults
600 mg (i.e. two 300 mg injections) SC once, and then 300 mg SC every other week.
Adverse Effect :
Herpes simplex infection, Oral herpes, antibody development, injection site reaction, conjunctivitis.
Interaction :
Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.
Vaccines (Live): Dupilumab may enhance the adverse/toxic effect of Vaccines.
Hepatic Dose :
No dosage adjustments are recommended.